Cited by 408Drug Transport and Resistance MechanismsBarrier Structure and Function StudiesAmino Acid Enzymes and Metabolism

Role of Monocarboxylate Transporters in Drug Delivery to the Brain

Open access
Vijay, Nisha, Morris, Marilyn·2014·Current Pharmaceutical Design

Abstract

Monocarboxylate transporters (MCTs) are known to mediate the transport of short chain monocarboxylates such as lactate, pyruvate and butyrate. Currently, fourteen members of this transporter family have been identified by sequence homology, of which only the first four members (MCT1- MCT4) have been shown to mediate the proton-linked transport of monocarboxylates. Another transporter family involved in the transport of endogenous monocarboxylates is the sodium coupled MCTs (SMCTs). These act as a symporter and are dependent on a sodium gradient for their functional activity. MCT1 is the predominant transporter among the MCT isoforms and is present in almost all tissues including kidney, intestine, liver, heart, skeletal muscle and brain. The various isoforms differ in terms of their substrate specificity and tissue localization. Due to the expression of these transporters in the kidney, intestine, and brain, they may play an important role in influencing drug disposition. Apart from endogenous short chain monocarboxylates, they also mediate the transport of exogenous drugs such as salicylic acid, valproic acid, and simvastatin acid. The influence of MCTs on drug pharmacokinetics has been extensively studied for γ-hydroxybutyrate (GHB) including distribution of this drug of abuse into the brain and the results will be summarized in this review. The physiological role of these transporters in the brain and their specific cellular localization within the brain will also be discussed. This review will also focus on utilization of MCTs as potential targets for drug delivery into the brain including their role in the treatment of malignant brain tumors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/13816128113199990462

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Abundant expression of monocarboxylate transporters in endothelial cells might facilitate crossing of the blood-brain barrier by short-chain fatty acids, since brain uptake of short-chain fatty acids has been demonstrated in rats following injection of 14C-SCFAs into the carotid artery.

    “The abundant expression of MCTs in endothelial cells (75, 92) might facilitate crossing of the BBB by SCFAs since brain uptake of SCFAs has previously been demonstrated in rats following injection of 14C-SCFAs into the carotid artery (93).”

    From The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication (2020) · cites this paper as [75]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • SCFAs can cross the BBB via monocarboxylate transporters (MCTs) on endothelial cells.

    “In vitro studies have shown that SCFAs can cross the BBB via monocarboxylate transporters (MCTs) on endothelial cells (Mitchell et al., 2011; Vijay & Morris, 2014).”
  • SCFAs maintain blood-brain barrier integrity through tight-junction protein regulation, as demonstrated in germ-free mice.

    “SCFAs also maintain blood–brain barrier (BBB) integrity through tight-junction protein regulation, as demonstrated in studies with germ-free mice [94,95,96].”
  • SCFA receptors, mainly free fatty acid receptors and monocarboxylate transporters, have been discovered in the central and peripheral nervous systems, indicating direct signaling potential.

    “Importantly, SCFA receptors, mainly free fatty acid receptors (349) and monocarboxylate transporters (350, 351), have been discovered in the central nervous system (CNS) and peripheral nervous system, indicating direct signaling potential.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. [21]Wilson MC Meredith D Fox JE Manoharan C Davies AJ Halestrap AP Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70) J Biol Chem 2005 280 27213 21 15917240
  2. [52]Tonduti D Vanderver A Berardinelli A MCT8 Deficiency: Extrapyramidal Symptoms and Delayed Myelination as Prominent Features J Child Neurol 2012 PMC4155008 22805248
  3. [65]Broer S Rahman B Pellegri G Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons J Biol Chem 1997 272 30096 102 9374487
  4. [86]Mac M Nalecz KA Expression of monocarboxylic acid transporters (MCT) in brain cells. Implication for branched chain alpha-ketoacids transport in neurons Neurochem Int 2003 43 305 9 12742073

Cited by

Sorted by citations

Authors
Vijay, N., & Morris, M.
Affiliations
University at Buffalo, State University of New York (US)
Venue
Current Pharmaceutical Design
Published
2014-03-31
Volume
20
Issue
10
Pages
1487-1498
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2043175749
Cited by
408
References
121
Citations by year
2026: 28 · 2025: 41 · 2024: 69 · 2023: 65 · 2022: 47 · 2021: 51 · 2020: 33 · 2019: 18 · 2018: 14 · 2017: 13 · 2016: 17 · 2015: 3 · 2014: 8 · 2013: 1
FWCI
6.60
Type
journal article
Language
en
Open access
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (DA 023223, R01DA023223)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
monocarboxylate transporters, MCT1, MCT4, brain drug delivery, lactate transport, pyruvate transport, pharmacokinetics, gamma-hydroxybutyric acid, drug disposition, brain tumor therapy, transporter isoforms
MeSH terms
Animals, Blood-Brain Barrier, Brain, Pharmaceutical Preparations, Humans, Drug Delivery Systems, Monocarboxylic Acid Transporters

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review